3 assets in Tumor Of Salivary Gland

Therapeutic assets addressing Tumor Of Salivary Gland, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pertuzumab Tumor Of Salivary Gland	Cancer Research UK	P2/3	B (57)
Trastuzumab Tumor Of Salivary Gland	Cancer Research UK	P2/3	B (57)
Ava-6000 (Fap-Activated Doxorubicin Prodrug) Tumor Of Salivary Gland	Avacta Life Sciences Ltd	P1	CC (43)